14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Monday, 6th May 2024 CANF stock ended at $2.11. This is 0.96% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 9.95% from a day low at $2.11 to a day high of $2.32.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Nov 04, 2022 $0.82 $0.85 $0.80 $0.84 76 522
Nov 03, 2022 $0.89 $0.89 $0.84 $0.85 18 697
Nov 02, 2022 $0.90 $0.90 $0.86 $0.89 142 448
Nov 01, 2022 $0.86 $0.89 $0.86 $0.89 81 799
Oct 31, 2022 $0.86 $0.90 $0.84 $0.87 153 872
Oct 28, 2022 $0.87 $0.90 $0.84 $0.88 56 926
Oct 27, 2022 $0.83 $0.90 $0.772 $0.86 174 243
Oct 26, 2022 $0.86 $0.86 $0.771 $0.80 141 616
Oct 25, 2022 $0.84 $0.86 $0.740 $0.83 1 213 067
Oct 24, 2022 $0.766 $0.766 $0.733 $0.754 28 841
Oct 21, 2022 $0.764 $0.789 $0.690 $0.747 35 828
Oct 20, 2022 $0.758 $0.787 $0.738 $0.750 16 708
Oct 19, 2022 $0.770 $0.770 $0.740 $0.770 28 077
Oct 18, 2022 $0.758 $0.770 $0.750 $0.759 31 363
Oct 17, 2022 $0.750 $0.750 $0.700 $0.733 82 728
Oct 14, 2022 $0.770 $0.770 $0.730 $0.740 43 179
Oct 13, 2022 $0.709 $0.738 $0.709 $0.738 17 832
Oct 12, 2022 $0.750 $0.750 $0.711 $0.729 15 544
Oct 11, 2022 $0.770 $0.770 $0.710 $0.721 28 915
Oct 10, 2022 $0.743 $0.769 $0.740 $0.740 24 773
Oct 07, 2022 $0.770 $0.793 $0.740 $0.783 36 510
Oct 06, 2022 $0.790 $0.800 $0.770 $0.779 26 572
Oct 05, 2022 $0.80 $0.80 $0.741 $0.780 56 044
Oct 04, 2022 $0.790 $0.790 $0.730 $0.789 57 490
Oct 03, 2022 $0.756 $0.770 $0.701 $0.730 100 337
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT